Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
Jorge Plutzky, Paweł Bogdański, Helen M Colhoun et al.
✦ AI-curated · Sources linked
In 30 seconds
This prespecified secondary analysis of the SELECT trial evaluated the impact of semaglutide on high-sensitivity C-reactive protein (hsCRP) levels in 17,604 patients with established cardiovascular disease and obesity. The study found that semaglutide reduced hsCRP levels by 37.8% at 104 weeks and was associated with a decreased risk of major adverse cardiovascular events (MACE), suggesting inflammation may play a role in cardiovascular risk reduction.
Key findings
- Baseline hsCRP levels were prognostic of future MACE risk.
- Semaglutide reduced hsCRP levels by 37.8% at 104 weeks.
- Greater hsCRP reductions correlated with greater weight loss, even before significant weight loss occurred.
- hsCRP reductions were independent of LDL cholesterol levels and statin use.
Why it matters
Understanding the relationship between inflammation and cardiovascular risk can help clinicians identify patients at higher risk and tailor treatment strategies. The findings suggest that targeting inflammation may enhance cardiovascular outcomes in patients with obesity and established cardiovascular disease.